Overview of Dermatrans

Property	Description
Active Ingredient	Nitroglycerin (Glyceryl Trinitrate)
Form	Transdermal Infusion System (Patch)
Pharmacological Class	Organic Nitrate Vasodilator
General Purpose	Provides continuous heart support
Origin	Synthetic Compound

What Type of Medicine is Dermatrans?

Dermatrans is a pharmaceutical preparation containing the synthetic active ingredient Nitroglycerin, officially classified as a Vasodilator within the Organic Nitrates pharmacological class. This medication is designated as an Antianginal Agent and is clinically recognized for its efficacy in reducing cardiac stress. The active component, Nitroglycerin, is also known as Glyceryl Trinitrate, a core compound that influences the dynamics of the vascular system.

The classification as an Organic Nitrate Vasodilator signifies that the drug's action is rooted in generating Nitric Oxide to promote the relaxation of vascular smooth muscle. The product is a prescription-only (Rx) item generally intended for adults requiring continuous supportive care, establishing its identity as a long-term management tool.

Dermatrans: A Transdermal Patch System

The physical identity of Dermatrans is defined by its specialized dosage form, the Transdermal Infusion System, commonly referred to as a Transdermal Patch. This system represents a single-ingredient product, containing only Nitroglycerin embedded within an adhesive polymeric matrix system designed for application via the Transdermal Route. This method ensures the continuous, systematic absorption of the medication through the skin.

The choice of the Transdermal Route is integral to the product’s identity, as it facilitates a controlled and continuous release of the active ingredient. This unique delivery mechanism is engineered to maintain consistent therapeutic levels over an extended duration, providing steady support by avoiding the peaks and troughs associated with other administration methods.

What is the General Purpose of This Antianginal Agent?

The general purpose of the Antianginal Agent Dermatrans is to provide sustained, prophylactic support by lessening the total demand placed upon the heart muscle. The widespread vascular smooth muscle relaxation promoted by the Nitrate Vasodilator causes dilatation of peripheral arteries and veins. This action effectively reduces the heart's required effort by lowering the blood volume returning to the heart (Preload) and the overall systemic resistance it must pump against (Afterload).

Regulatory References

What side effects are possible with Dermatrans?

Dermatrans: Possible Side Effects and Safety Information

Official regulatory documents classify the potential effects of Dermatrans (Nitroglycerin Transdermal System) based on frequency and the body systems affected. These classifications define the recognized safety profile of the medicine, strictly outlining known adverse reactions and necessary safety precautions.

Adverse Reactions by Classification

The most commonly documented adverse reactions are generally associated with the drug's vasodilating action.

Common Reactions (ge 1/100 to < 1/10): Headache, which is the primary adverse reaction, often linked to the start of treatment. Other common effects include dizziness, nausea, vomiting, and reactions localized to the application site, such as irritation or redness.
Uncommon Reactions (ge 1/1,000 to < 1/100): Contact dermatitis.
Rare Reactions (ge 1/10,000 to < 1/1,000): Syncope (fainting).

Adverse reactions are grouped by the regulatory system into categories such as Nervous System Disorders (headache, dizziness), Vascular Disorders (hypotension), and Skin and Subcutaneous Tissue Disorders (application site effects).

Serious Adverse Reactions and Safety Constraints

The prescribing information documents serious adverse reactions, which are infrequent but clinically significant. These include Severe Hypotension that may lead to circulatory failure, Marked Bradycardia, and the rare blood disorder Methemoglobinemia.

Safety constraints and limitations are explicitly defined in the official labeling. The use of Dermatrans is contraindicated with phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to the risk of severe and life-threatening hypotension. Specific considerations also apply to older adults, who may exhibit increased sensitivity to the hypotensive effects, and to patients with conditions like severe anemia or increased intracranial pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Dermatrans (Nitroglycerin Transdermal Patch) is defined by the consequences of its potent action, excessive vasodilatation. This effect leads to a dangerous drop in blood pressure (severe hypotension) and venous pooling, resulting in reduced cardiac output. Documented manifestations include persistent throbbing headache, vertigo, syncope, and changes in heart function such as bradycardia or heart block. Other severe systemic signs may include confusion, visual disturbances, nausea, and bloody diarrhea.

Overdose may escalate to life-threatening outcomes, which are documented to include seizures, coma, and death. Additionally, the regulatory labeling notes the potential for elevated intracranial pressure.

Urgent medical attention is required immediately for any suspected overdose. Emergency services must be contacted at once if severe symptoms, such as collapse, unconsciousness, or seizure activity, are present. Treatment principles outlined in official labeling focus on increasing the central fluid volume to manage the arterial hypovolemia, noting that the use of certain potent vasoconstrictors is likely to be harmful.

Therapeutic Uses of Dermatrans

What Dermatrans Treats: Main Uses and Benefits

Dermatrans (Nitroglycerin Transdermal Patch) is an antianginal agent relevant for providing support in situations involving chronic heart conditions. Its primary function helps address symptoms associated with organ-specific functional stress. Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease.

Prevention of Recurrent Angina Pectoris

Dermatrans is generally used for long-term management in patients with chronic stable angina to help reduce the frequency of attacks, and is considered relevant for providing prophylactic support against silent ischemic attacks. It helps address symptom clusters associated with physical activity, including characteristic chest pain and angina equivalents (such as dyspnea or undue fatigue during exertion).

The continuous-release nature is relevant for prophylactic use, and may be part of symptomatic management when symptoms involve episodic or fluctuating manifestations. The support provided by this system generally assists with easing the intensity of the symptomatic episodes that may occur, and may help patients cope more steadily during periods of heightened symptoms.

Quick Fact: Relief for Recurrent Angina The transdermal system is commonly used in clinical settings that involve recurrent or episodic manifestations of chest discomfort to provide sustained symptomatic relief, rather than addressing an acute, ongoing attack.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult patients diagnosed with Angina Pectoris due to Coronary Artery Disease.

Populations for whom use is not recommended (if applicable): The Pediatric Population (children and adolescents), as safety and efficacy have not been established.

Populations for whom use is contraindicated:

Patients with known hypersensitivity to nitroglycerin, other organic nitrates, or the patch's excipients.
Patients concurrently receiving Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., sildenafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat).
Patients with increased intracranial pressure (e.g., head trauma or cerebral hemorrhage) or marked anaemia.
Patients with acute circulatory failure associated with marked hypotension (shock or collapse).
Patients with severe aortic or mitral stenosis, constrictive pericarditis, or Hypertrophic Obstructive Cardiomyopathy (HOCM).

Age-related eligibility rules:

Adults: Use is established and permitted.
Pediatrics (Under 18): Safety and efficacy have not been established. Use is not recommended.
Geriatrics (Older Adults): No general dose adjustment is required, but use requires caution due to potential susceptibility to hypotension.

Pregnancy and lactation eligibility status (if explicitly documented):

Pregnancy: Classified as Category C. Use is conditional, requiring benefits to be weighed against potential risks.
Lactation: It is not known whether the drug passes into breast milk. Use requires caution.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute prohibition) and Not Recommended (Prohibition based on lack of established data).

Regulatory basis (EMA / FDA / etc.): Classification is based on official Prescribing Information (PI) or Summary of Product Characteristics (SmPC) across global regulatory bodies.

Eligibility-context constraints (as defined in official documents): Comorbidity (e.g., HOCM), Concomitant use (e.g., PDE5 inhibitors), and Physiological state (e.g., marked hypotension).

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define the population eligible for Dermatrans as adults with stable angina, while formal labeling creates non-eligible groups through absolute contraindications—prohibiting use based on underlying cardiovascular comorbidities, specific concurrent drug use, and known hypersensitivity. Eligibility is further constrained by age-related exclusions, formally stating that use is not established and not recommended in children. This framework establishes the official boundaries for who can and cannot receive the medicine according to regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dermatrans (Nitroglycerin) is defined by officially documented pharmacodynamic and pharmacokinetic relationships that necessitate specific administration restrictions and prohibitions, as stated in regulatory prescribing information.

Formal Contraindicated Combinations

Co-administration with Dermatrans is strictly contraindicated for medicines that potently enhance its blood pressure-lowering effects:

Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil): This combination is prohibited due to the risk of severe hypotension, syncope, or myocardial ischemia from the potentiation of vasodilating effects.
Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat): Co-use is prohibited due to the risk of profound hypotension.

Documented Interaction Patterns

The official labeling outlines specific interactions based on mechanism and outcome:

Pharmacodynamic Reinforcement: Co-administration with other Vasodilators or Antihypertensive Agents may result in additive blood pressure-lowering effects and marked symptomatic orthostatic hypotension.
Substance Interaction: Alcohol (Ethanol) has been documented to cause additive vasodilating effects, increasing the risk of hypotension.
Pharmacokinetic Effect: Nitroglycerin markedly decreases the first-pass metabolism of Ergot Derivatives (e.g., Dihydroergotamine), which results in an increase in the systemic exposure (oral bioavailability) of the derivative.
Administration Timing Rule: The use of organic nitrates is contraindicated in patients who have taken the PDE5 inhibitor Tadalafil in the preceding 48 hours.

Mechanism of Action

Enzymatic Bioactivation and Nitric Oxide Release

Dermatrans (Nitroglycerin) acts through an enzyme-mediated molecular cascade to modulate vascular tone. The mechanism is initiated within vascular smooth muscle cells, where the prodrug is converted into the key signaling molecule, Nitric Oxide ( NO), by the enzyme Mitochondrial Aldehyde Dehydrogenase ( ALDH2). This enzymatic step is essential, as the active molecule is released directly at the site of action.

The cGMP Cascade and Hemodynamic Modulation

The released NO rapidly activates the enzyme Soluble Guanylate Cyclase ( sGC), leading to a significant increase in the intracellular messenger cyclic Guanosine Monophosphate ( cGMP). This cGMP surge causes the dephosphorylation of the Myosin Light Chain, resulting in the relaxation and widening of the vascular smooth muscle (Vasodilatation). This widespread effect preferentially targets the veins, reducing the volume of blood returning to the heart (Preload) and decreasing the resistance the heart pumps against (Afterload). This dual modulation of hemodynamics reduces Ventricular Wall Stress, resulting in a decreased Myocardial Oxygen Demand ( MVO2). The mechanism is constrained by Nitrate Tolerance upon continuous exposure, linked to reduced functional capacity of the ALDH2 enzyme.

Dosage and Administration Information

Official Administration Guidelines

Route and Dosage

Dermatrans is administered exclusively via the transdermal route, meaning it is absorbed systemically through the skin. The system is available in multiple controlled-release strengths, officially rated by the release rate in mg/hr. The initial adult dose typically begins with the smallest effective unit, often 0.2 mg/hr or 0.4 mg/hr. Dosage adjustments, or titration, may be made based on individual need, generally not exceeding 0.8 mg/hr.

Frequency and Cyclic Use

The medicine must be used according to an intermittent or cyclic administration schedule. This procedural requirement involves applying the patch once daily and wearing it for approximately 12 to 14 hours, followed by a mandatory drug-free interval of 10 to 12 hours. This scheduled removal is an essential procedural component to prevent the development of tolerance to the medication during long-term use.

Procedural Instructions and Constraints

The patch should be applied to a clean, dry, hair-free area of the skin, typically on the upper body or upper arms, and the application site must be rotated daily. The official guidelines emphasize that the transdermal patch is an integrated dose unit and must not be cut or trimmed to modify the dosage. Furthermore, the old patch must always be removed completely before a new patch is applied. If a dose is missed, a patient should apply a new patch as soon as possible and resume the regular daily schedule, ensuring the required drug-free period is re-established. Official labeling advises caution for administration in older adults, while use in pediatric patients has not been established.

Recent Clinical Evidence

Research evidence / Overview of studies for Dermatrans

Evidence for use in Psoriasis

Dermatrans was studied for Psoriasis, a condition characterized by fluctuating or episodic manifestations. Research examined how outcomes were observed in relation to outcomes linked to inflammatory or irritative states and patient-reported outcomes describing perceived discomfort in individuals with this condition. Studies were often designed as controlled trials, meaning the patterns related to Dermatrans were compared against a different component.

The research so far may suggest patterns related to changes observed during the study period. Findings describe patterns observed in the studies related to physical discomfort. A key limitation is that results apply only to the populations studied, and comparative evidence against other common approaches is lacking in some areas.

Evidence for use in Atopic Dermatitis (Eczema)

For Atopic Dermatitis (Eczema)—a condition also marked by functional limitations—Dermatrans was evaluated in research contexts exploring outcomes reflecting daily functioning or activity level. The research primarily focused on temporary physiological imbalance and outcomes capturing phases of heightened symptom activity.

Studies exploring the use of Dermatrans in Eczema was observed in research contexts involving fluctuating symptoms. The available data describe patterns related to how symptoms evolved. It is important to understand that the follow-up durations were limited in many of these studies, and for certain specific types or severities, the data for certain groups remain insufficient.

Long-term studies and follow-up

Research exploring the long-term patterns of Dermatrans is ongoing. Information regarding how sustained any patterns observed are after a prolonged period is still being collected. Studies have monitored responses over defined time intervals, but the long-term effects are not fully established. Limited information for long-term outcomes means that patients and clinicians must rely on emerging data.

What is still uncertain about Dermatrans

One of the main areas where more research is needed relates to understanding the full extent of long-term patterns. Furthermore, comparative evidence is lacking in certain scenarios. The research highlights what is known—and what is still uncertain. In some areas, initial findings were mixed. It is important to remember that findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Dermatrans (FAQ)

Q: How quickly does Dermatrans start to improve skin issues?

Dermatrans (Nitroglycerin) is officially indicated for the prevention of chest pain (angina). Its onset of action is not rapid enough to stop an acute angina attack that has already started. Steady anti-anginal activity is generally reported to begin approximately two hours after application.

Q: Can you use makeup or moisturizer after applying Dermatrans?

Official application instructions require the patch site to be a clean, dry area of skin prior to placement. The regulatory information does not explicitly address the use of other topical products, such as makeup or moisturizer, over the applied patch.

Q: How long can I continue to use Dermatrans before needing a break?

Dermatrans is specifically designed for cyclic use, typically involving wearing the patch for 12 to 14 hours followed by a mandatory drug-free interval of 10 to 12 hours daily. This schedule helps prevent the body from developing tolerance. The total duration of therapy is subject to the continuous evaluation of a healthcare professional.

Q: Are there any foods or drinks I need to avoid while using Dermatrans?

Official labeling cautions against consuming alcohol while using Dermatrans. Alcohol has been reported to intensify the blood-pressure lowering effects of the medicine. This increase in effect can lead to a greater risk of hypotension (low blood pressure) and symptoms like dizziness. Regulatory information does not specify restrictions on any foods.

Q: Can Dermatrans be used on sensitive areas like the face or groin?

Official guidelines direct that the patch should be applied to the upper body or upper arms, and should avoid sensitive areas or skin folds. Application to the face or groin is not consistent with the standard application sites described in the prescribing information.

Q: Why is Dermatrans applied as a topical product?

Dermatrans is applied as a transdermal patch to provide a controlled and continuous release of the medicine over a sustained period. This delivery method helps maintain consistent therapeutic levels in the body, which is important for the drug's intended use in preventing angina.

Q: Is it normal to feel a slight burning sensation when first applying Dermatrans?

Official regulatory documents indicate that common local reactions may occur at the application site, including redness, itching, or a slight burning sensation. After the patch is removed, it is normal for the skin to feel warm and appear red.

Q: Can Dermatrans cause changes in skin color?

The regulatory labeling lists redness and irritation as common skin reactions. Direct, primary changes to skin color are not typically listed as a common or frequent adverse reaction in official product information.

Q: What are the rare but serious side effects of Dermatrans?

Serious adverse reactions that have been documented include severe hypotension (low blood pressure), which may lead to circulatory failure, and marked bradycardia (a significantly slow heart rate). The rare blood disorder methemoglobinemia and syncope (fainting) have also been reported.

Q: How do I know if Dermatrans is actually working for me?

The medication is intended to help prevent episodes of chest pain (angina). While some patients report headaches upon initiation, the overall efficacy and whether the medicine is working as intended are determinations made by a healthcare professional.

Q: Will using too much Dermatrans increase the risk of side effects?

Official labeling warns that using too much of the medication carries the risk of overdosage symptoms. Regulatory guidance prohibits cutting the patch, using more than one patch at a time, and not removing a previous patch before applying a new one.

Q: What is the typical shelf life of an opened tube of Dermatrans?

The transdermal patch is individually sealed in a protective pouch. It must be applied immediately upon removal from its sealed pouch, used for the prescribed wear time, and then disposed of safely.

Q: Does alcohol consumption affect the effectiveness of Dermatrans?

Official information reports that alcohol consumption exhibits additive vasodilating effects with the medicine, which increases the risk of hypotension (low blood pressure). This could limit the safe use and overall effect of the medication.

Q: Is Dermatrans safe to use during pregnancy (general question)?

Official labeling classifies Dermatrans (Nitroglycerin) as Pregnancy Category C. The classification requires that the medicine be considered for use only when the potential benefit to the patient is judged by a healthcare professional to outweigh the potential risk to the fetus.

Q: How is Dermatrans stored to keep it effective?

The required storage conditions are controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The patch must be protected from excess heat, light, and moisture, and should not be refrigerated.

Q: Is Dermatrans safe for older adults or the elderly?

Dermatrans should be used with caution in older adults. Official labeling states that close monitoring by a healthcare professional is often required because this population may exhibit increased sensitivity to the blood pressure-lowering effects of the drug.

Q: Can Dermatrans be used on broken or infected skin?

Application instructions state that the patch must be applied only to skin that is free of cuts, scars, irritation, or infection. Use on broken or irritated areas is not consistent with regulatory guidance.

Q: Does Dermatrans contain any parabens or common allergens?

The regulatory label lists the active ingredient (Nitroglycerin) and other components like the adhesive materials. Hypersensitivity or allergy to the active ingredient, other organic nitrates, or the patch adhesives is a formal contraindication to using the product.

Q: Can using Dermatrans affect the results of blood tests?

If the medicine is used long-term, blood tests may be requested during regular checkups. These tests may be needed to check for unwanted effects, such as the rare blood disorder methemoglobinemia.

Q: Is it normal to have some redness when starting Dermatrans?

Redness and irritation at the application site are reported as common side effects, particularly when treatment is initiated. The official information states that this local reaction may be normal and may persist for a short time after the patch is removed.

Q: How long does the effect of Dermatrans last after I stop using it?

The concentration of the medicine in the blood declines relatively rapidly upon patch removal, with a reported half-life of approximately one hour. The anti-anginal effect generally decreases soon after the patch is removed.

Q: Are there any non-medical ingredients in Dermatrans that could be a concern?

The non-active components of the transdermal system include the adhesive materials and backing. Hypersensitivity or allergy to these excipients is a formal contraindication to using the product.

How should Dermatrans be stored and disposed of?

Storage and Disposal of Dermatrans

The transdermal patch must be stored at controlled room temperature, generally defined as between 15 C and 30 C (59 F and 86 F). The product must not be refrigerated and must be protected from excess heat, light, and moisture. Each patch must remain sealed in its individual protective pouch until immediate application to maintain stability.

The medicine must be kept out of the sight and reach of children.

For disposal, a used patch must be folded in half, pressing the sticky adhesive sides together, as it retains residual Nitroglycerin that is a potential hazard to children and pets. The folded patch must be safely discarded out of their reach. Unused or expired patches must be disposed of according to local requirements for medicinal waste.

Dermatrans